drugset / Trial / NCT07049328
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Timeline
- Start
- 2025-08-16
- Primary completion
- 2026-07-16
- Completion
- 2026-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCW9302 | Protein / enzyme biologic | — | Subcutaneous |